701 Gateway Blvd Ste 210
South San Francisco, CA, 94080 United States
(650) 635-7000 †
Mateon Therapeutics (formerly OXiGENE) is a biopharmaceutical company focused on vascular targeted therapy in oncology, which starves cancer to death. Its vascular targeted therapy include vascular disrupting agents (VDAs) and anti-angiogenic agents (AAs). VDAs selectively obstruct a tumor's blood supply without obstructing the blood supply to normal tissues, and treatment with our VDAs has been shown to lead to significant central tumor necrosis. Mateon believes that the treatment of cancer is significantly improved if VDAs and AAs are used together. The company's strategy is to identify and license compounds from academic research centers and then shepherd the compounds through clinical trials.
† Some telephone numbers on the Hoover’s site may be on a country’s do not call or do not contact list including, but not limited to, the United Kingdom’s CTPS or TPS registers. It is a legal requirement that companies do not make sales or marketing calls to registered numbers. These are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls. By using the information provided on the Hoover’s sites, as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local, state, national or international laws and regulations, including any local do not call registers or marketing regulations, and agree to defend, indemnify and hold harmless Dun & Bradstreet and each of its affiliates in the event your use violates such laws and regulations.